1. Yi SY, Kim HS, Jun HJ, Yang JH, Ko YH, Ki CS, Kim WS Quantifing the Circulating Epstein-Barr Virus (EBV) DNA to Monitor a Case of Aggressive Natural Killer Cell Leukemia. Korean J Hematol 2007 42(2):167-171

2. Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009 May;63(6):1141-5.

3. Yi SY, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer. 2010 Oct 5; 10:527.

4. Won YW, Yi SY, Jang JH, Kim K, Kim SJ, Kim WS, Jung CW, Kim DH. Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2011 Mar;93(3):383-8.

5. Park JY, Yi SY, Park HJ, Kim MS, Kwon HJ, Park NH, Moon SY. Breast-specific gamma imaging: correlations with mammographic and clinicopathologic characteristics of breast cancer. AJR Am J Roentgenol. 2014 Jul;203(1):223-8.

6. Ku BM, Yi SY, Koh J, Bae YH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13.

외 SCI 제 1저자, 공저자 55편